Patrick Lin - 26 Jul 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Business - Strategy Off
Issuer ticker: PCSA
Reported as of: 26 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 20:23:51 UTC
Prior SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact

Key filing fact

Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 28 Jul 2026.

Key facts

This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 28 Jul 2026, 20:23.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001799363 Primary reporting owner

Lin Patrick

Relationship: Chief Business - Strategy Off
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact
Signature date: 28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCSA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,113
Date: 26 Jul 2026
Ownership: Direct

PCSA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,740
Date: 26 Jul 2026
Ownership: Lin Family Trust Feb 4, 2024

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +8,450
Change %: +288%
Price: $0.000000^*
Shares after: 11,389
Date: 26 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,450
Exercise price: $0.000000
Footnotes: F1, F3

PCSA holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,160
Date: 26 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,160
Exercise price: $4.96
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

Footnote F2

Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

Footnote F3

Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.